Left ventricular assist devices are becoming an increasingly prevalent therapy for patients with Stage D heart failure with reduced ejection fraction. Technological advances have improved the durability of these devices and have significantly lengthened survival in these patients. Quality of life is also improved, although adverse events related to device therapy Left ventricular ejection fraction <25%; and Functional limitation with a peak oxygen consumption <14 ml/kg/min, unless on an intra-aortic balloon pump, IV inotropes, or physically unable to perform the exercise test.
SURGICAL THERAPIES. The greatest advances in HFrEF therapy over the last decade have been surgical approaches (7) (8) (9) . Biventricular pacing has resulted in improved survival, reverse remodeling, and improved quality of life (10) Illustration. In this algorithm, the initial screen is eligibility for cardiac transplantation, followed by assessment for destination mechanical support, and eventually, palliation. Indeed, in the 2013 International Society of Heart Lung Transplant guidelines for use of mechanical devices, the initial question asked is whether the patient is to be considered a transplant candidate (11) . With the rapid advances in mechanical circulatory support, this algorithm may be revised in the near future such that the initial question is eligibility for destination therapy (DT), followed by heart transplantation candidacy and palliation (Central Left ventricular ejection fraction <25%; and Functional limitation with a peak oxygen consumption <14 ml/kg/min, unless on an intra-aortic balloon pump, IV inotropes, or physically unable to perform the exercise test.
Separation of LVAD patients into bridge to transplant (BTT) and DT populations has been problematic.
During their acute illness, many patients may fall into a gray zone with comorbidities that reverse over time.
These patients are frequently categorized as "bridge to decision." In an attempt to normalize end-organ function that currently precludes long-term cardiac replacement therapies, these patients are often supported using extracorporeal membrane oxygenation or short-term single or biventricular assist devices.
Selection criteria for DT are less rigid, in some respects, than for transplant candidacy. Table 1 The need for adequate social support is required for both transplant and mechanical assist device patients, but it is more imperative for device candidates, who may need immediate assistance at home in the event of a serious device alarm.
Age is a key criterion for acceptance for heart transplant that has generated much debate. Some centers will accept candidates in the seventh decade of life, whereas other centers are more conservative (34) (35) (36) Despite these differences, the 2-year survival rates post-LVAD or -transplant were comparable. Whether the long-term outcomes would be similar is unknown.
The choice of the ideal therapy for these patients needs to be studied in a prospective trial. Only recently, as devices became more durable, portable, and user-friendly, has this practice pattern begun to evolve toward DT (7) (8) (9) 19, (43) (44) (45) . Table 2 summarizes the major clinical trials assessing survival on long-term LVADs. Components include a surgically implanted pump that works in parallel with the native heart via an inflow cannula to the left ventricle and an outflow graft to the ascending aorta, a percutaneous driveline, a system controller and electrically powered batteries with a life span up to 12 h (A). Features of continuous-flow axial (B), centrifugal (C), and mixed design pumps, where the pump is axial but blood exits perpendicular to the inflow like in centrifugal pumps (D), are also shown. Pump speed modulation can be independent of the native heart rate (asynchronous) or consistent with native heart rate (synchronous). Synchronous term support, the latter of which has already been described in several cases using HVADs (64), thus preventing the need for a totally artificial heart in severe biventricular failure.
T o t a l i m p l a n t a b i l i t y . A fully-implantable system that is rechargeable transcutaneously is an option desired by patients. However, several technical challenges remain. Two large discontinued pulsatile systems, the AbioCor total artificial heart and the 
